3-heptylamino-5-phenylpyridazine derivatives as analogues of Acyl-CoA: cholesterol acyltransferase inhibitors containing the N-heptyl-N'-arylureidic moiety = 페닐피리다진 유도체의 ACAT 저해활성

Cited 1 time in scopus
Metadata Downloads

Full metadata record

DC FieldValueLanguage
dc.contributor.authorA Gelain-
dc.contributor.authorD Barlocco-
dc.contributor.authorByoung-Mog Kwon-
dc.contributor.authorTae Sook Jeong-
dc.contributor.authorKyung-Ran Im-
dc.contributor.authorL Legnani-
dc.contributor.authorL Toma-
dc.date.accessioned2017-04-19T09:05:41Z-
dc.date.available2017-04-19T09:05:41Z-
dc.date.issued2006-
dc.identifier.issn0365-6233-
dc.identifier.uri10.1002/ardp.200600106ko
dc.identifier.urihttps://oak.kribb.re.kr/handle/201005/7717-
dc.description.abstractA series of novel Acyl-CoA: cholesterol acyltransferase (ACAT) inhibitors 8a-f was synthesized; the substances were characterized by the presence of a 2,5-dimethylpyrazin-3-yl moiety at one end and a 3-heptylamino-5- phenylpyridazine system at the other one, linked through linear alkyl spacers of different length. The new derivatives were designed based on the hypothesis that the 3-amino-5-phenylpyridazine moiety could mimic the aryl substituted urea, which was present in a number of ACAT inhibitors previously described. The choice of the 2,5-dimethylpyrazin-3-yl substituent was supported by a preliminary investigation, which indicated that this moiety is the most powerful in conferring ACAT inhibitory properties to the new series. The pharmacological results proved the idea to be sound. Finally, compounds 9a-c, lacking the phenylpyridazine moiety were prepared and tested to further strengthen our hypothesis.-
dc.publisherWiley-
dc.title3-heptylamino-5-phenylpyridazine derivatives as analogues of Acyl-CoA: cholesterol acyltransferase inhibitors containing the N-heptyl-N'-arylureidic moiety = 페닐피리다진 유도체의 ACAT 저해활성-
dc.title.alternative3-heptylamino-5-phenylpyridazine derivatives as analogues of Acyl-CoA: cholesterol acyltransferase inhibitors containing the N-heptyl-N'-arylureidic moiety-
dc.typeArticle-
dc.citation.titleArchiv der Pharmazie-
dc.citation.number12-
dc.citation.endPage651-
dc.citation.startPage645-
dc.citation.volume339-
dc.contributor.affiliatedAuthorByoung-Mog Kwon-
dc.contributor.affiliatedAuthorTae Sook Jeong-
dc.contributor.affiliatedAuthorKyung-Ran Im-
dc.contributor.alternativeNameGelain-
dc.contributor.alternativeNameBarlocco-
dc.contributor.alternativeName권병목-
dc.contributor.alternativeName정태숙-
dc.contributor.alternativeName임경란-
dc.contributor.alternativeNameLegnani-
dc.contributor.alternativeNameToma-
dc.identifier.bibliographicCitationArchiv der Pharmazie, vol. 339, no. 12, pp. 645-651-
dc.identifier.doi10.1002/ardp.200600106-
dc.subject.keywordACAT inhibitors-
dc.subject.keywordhypercholesterolemia-
dc.subject.keywordpyridazine derivatives-
dc.subject.keywordureido analogues-
dc.subject.localACAT inhibitor-
dc.subject.localACAT inhibitors-
dc.subject.localHypercholesterolemia-
dc.subject.localhypercholesterolemia-
dc.subject.localpyridazine derivatives-
dc.subject.localureido analogues-
dc.description.journalClassY-
Appears in Collections:
Division of A.I. & Biomedical Research > Microbiome Convergence Research Center > 1. Journal Articles
Files in This Item:
  • There are no files associated with this item.


Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.